Evelo Biosciences Provides Clinical Updates
26 avr. 2023 07h30 HE
|
Evelo Biosciences, Inc.
– Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint –– Company will focus on development of extracellular vesicles (EVs) –– First EV...
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
09 mars 2023 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered...
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference
01 mars 2023 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory...
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
27 févr. 2023 06h00 HE
|
Evelo Biosciences, Inc.
– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns – – Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been...
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
14 nov. 2022 17h27 HE
|
Evelo Biosciences, Inc.
- Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 - - Phase 2 data for first...
Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
07 sept. 2022 01h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting...
Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference
01 sept. 2022 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting...
Evelo Biosciences Announces Succession Plan
11 août 2022 06h01 HE
|
Evelo Biosciences, Inc.
– Simba Gill to transition to Chair of the Board of Directors –– Lord Ara Darzi will become Lead Independent Director –– Board has retained Spencer Stuart for Chief Executive Officer search – ...
Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights
11 août 2022 06h00 HE
|
Evelo Biosciences, Inc.
– Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end –– Two Phase 2 clinical read-outs with EDP1815 in atopic dermatitis expected in 1Q and 2Q 2023 –– Phase...
Evelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
05 août 2022 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...